What Is The Long-Term Forecast For The Global Radioligand Therapy Market Growing At 10.1% CAGR?
Uncover key drivers, emerging technologies, and competitive movements shaping the radioligand therapy market from 2025–2034 with trusted insights from The Business Research Company
What Are The Market Size Estimates For The Radioligand Therapy Market?
The radioligand therapy market has witnessed rapid expansion in recent years. This market is anticipated to increase from $6.01 billion in 2024 to $6.64 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.5%. The historical growth of this market can be attributed to several factors, including the rising utilization of liquid biopsy, the advent of tumor-agnostic therapies, the integration of artificial intelligence within oncology, a growing pipeline of bispecific antibodies, and an increase in government funding directed towards cancer initiatives.
The radioligand therapy market is poised for significant expansion in the coming years. It is forecast to reach $9.77 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.2%. This growth over the forecast period stems from factors such as increasing investments by large pharmaceutical firms in oncology startups, greater use of real-world evidence, advancements in radiopharmaceutical and theranostics research, expanding collaborations between academic and industrial sectors, and the rising incidence of rare and orphan cancers. Prominent trends for the forecast duration encompass AI-driven radiopharmaceutical design, theranostics featuring dual imaging-therapy platforms, microfluidics-based radiotracer synthesis, the development of next-generation alpha-emitting isotopes, and the deployment of 3D-printed personalized dosimetry devices.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp
What Drivers Are Accelerating Expansion Of The Radioligand Therapy Market?
Rising occurrences of cancer are projected to stimulate expansion within the radioligand therapy market. Cancer is defined as a condition characterized by the unchecked proliferation of atypical cells, capable of infiltrating adjacent tissues and disseminating across the body. The prevalence of cancer is escalating, attributed to prolonged contact with environmental contaminants that harm DNA, impair cellular processes, and foster irregular cell development. Radioligand therapy provides a cancer treatment method by delivering radiation directly to tumor cells using ligands that attach to particular receptors, thereby reducing damage to healthy tissues and eradicating cancer cells from within. For example, in January 2022, data from the American Cancer Society, a US-based non-profit organization focused on cancer awareness, projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-attributed fatalities in the US, translating to roughly 1,670 deaths per day. Consequently, the heightened occurrence of cancer is propelling the expansion of the radioligand therapy market.
What Are The Key Segment Trends Observed In The Radioligand Therapy Market?
The radioligand therapy market covered in this report is segmented
1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings
Subsegments:
1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)
Which Disruptive Trends Are Driving Change Across The Radioligand Therapy Market?
Major companies in the radioligand therapy market are prioritizing the development of advanced solutions, such as specialized radioligand therapy facilities, to boost production efficiency and uphold consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. These radioligand therapy facilities are dedicated centers designed for the handling and delivery of radioactive drugs for targeted cancer treatment, utilizing sophisticated imaging systems and radiation shielding, while ensuring safety through trained staff and stringent protocols. For instance, in January 2024, Novartis AG, a pharmaceutical company based in Switzerland, disclosed the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This facility has secured Food and Drug Administration (FDA) approval for commercial manufacturing. Covering 70,000-square-foot, this site is Novartis’s largest and most advanced facility exclusively for RLT, structured for efficient, time-sensitive production, and includes strategies for fully automated production lines, enabling significant increases in supply to meet rising patient demand in the US and Canada.
Who Are The Major Stakeholders Operating In The Radioligand Therapy Market?
Major companies operating in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc., OncoSil Medical Ltd.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report
What Regional Factors Are Accelerating Growth In The Radioligand Therapy Market?
North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp
Browse Through More Reports Similar to the Global Radioligand Therapy Market 2025, By The Business Research Company
Property Management Service Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report
Financial Accounting Advisory Services Global Market Report 2025
Real Estate Agency And Brokerage Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
